Aligos Therapeutics Reports Q3 2025 Progress and Financials

Aligos Therapeutics, Inc. ( (ALGS) ) has released its Q3 earnings. Here is a breakdown of the information Aligos Therapeutics, Inc. presented to its investors.

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for liver and viral diseases, leveraging its scientific expertise to address unmet medical needs such as chronic hepatitis B virus infection and metabolic dysfunction-associated steatohepatitis.

In its recent earnings report for the third quarter of 2025, Aligos Therapeutics highlighted significant progress in its clinical trials and financial performance. The company is advancing its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus infection, with enrollment underway across multiple countries. Additionally, Aligos is exploring partnerships for its obesity and MASH treatment, ALG-055009.

Financially, Aligos reported cash, cash equivalents, and investments totaling $99.1 million as of September 30, 2025, indicating a strong financial position compared to $56.9 million at the end of 2024. The net loss for the quarter was $31.5 million, with increased research and development expenses due to ongoing clinical trials. Despite the losses, the company maintains sufficient funding for operations into the third quarter of 2026.

The company’s strategic focus on its pipeline, particularly the potential of pevifoscorvir sodium as a leading therapy for chronic hepatitis B, underscores its commitment to advancing innovative treatments. Aligos is also actively seeking opportunities to fund and out-license its promising therapies for obesity and MASH.

Looking ahead, Aligos Therapeutics remains optimistic about its development pipeline and financial health, with anticipated data readouts and presentations in 2026 and beyond, positioning the company for potential growth and partnerships in the biotechnology sector.